MORGANTOWN, W.Va., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. (OTCQB:PRGB) ("Protea", "the Company") announced today that its CEO and Chairman, Stephen Turner, will present at the 7th annual LD Micro "Main Event" Micro-Cap Growth Conference on Thursday, Dec. 4 at 1:00 p.m. PT. The conference will be held at the Luxe Sunset Bel Air Hotel, in Los Angeles, California.
Mr. Turner will provide an update on the Company's business development and its collaborations with InSphero AG for the molecular analysis of 3D micro tissues, and with the Memorial Sloan Kettering Cancer Center (MSKCC) for the molecular analysis of early stage lung cancer.
The presentation will be available as a live and archived webcast at http://wsw.com/webcast/ldmicro7/ttnp. The replay will be available for 90 days following the live broadcast. Interested parties may also access the webcast from the Protea website at www.proteabio.com.
About Protea Biosciences Group, Inc.
Protea Biosciences Group, Inc. (OTCQB:PRGB) is a molecular information company providing innovative bioanalytical solutions to the pharmaceutical and life science industries. "Molecular information" refers to the generation and bioinformatic processing of very large data sets, obtained by applying the Company's technology to identify and characterize the proteins, metabolites, lipids and other biomolecules which are the byproducts of all living cells and life forms.
The Company is applying its technology to the development of next generation, "direct molecular imaging" technology and service capabilities that enable a more rapid and comprehensive molecular profile of human disease.
About LD Micro
LD Micro is an investment newsletter firm that provides self-directed investors information on selected public companies. Since 2002, the firm has published reports on select companies throughout the year. The firm hosts the LD Micro "Main Event" Micro-Cap Growth Conference for investors in December of each year. This year's conference will feature presentations by over 240 publicly traded companies, and is expected to attract more than 1,000 attendees. For additional information, please visit the LD Micro conference website at www.ldmicro.com.
Forward-Looking Statements
This press release may contain certain statements relating to future results, which are forward looking statements. These statements are not historical facts, but instead represent only the company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the company's control. It is possible that the company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the company and its business, including factors that potentially could materially affect the company's financial results, are contained in the company's filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
For more Information:
Protea Biosciences Group, Inc., 955 Hartman Run Road, Morgantown, WV 26505 USA
Phone: 304.292.2226
Fax: 304.292.7101
steve.oloughlin@proteabio.com
https://proteabio.com/investors
Protea and LAESI are registered trademarks of Protea Biosciences Group, Inc.